Press Release: First-Ever Gene Therapy Approved for Hemophilia B
FOR IMMEDIATE RELEASE First-Ever Gene Therapy Approved for Hemophilia B National patient advocacy organization issues formal statement. WASHINGTON, D.C., Nov. 23, 2022—Hemophilia Federation of America (HFA), a national advocacy leader for patients with bleeding disorders, released a statement considering recent news that the U.S. Federal Food and Drug Administration (FDA) approved CSL Behring’s (CSL) HEMGENIX® […]
HFA Statement on FDA Approval of First-Ever Gene Therapy for Hemophilia B
Five years ago, Hemophilia Federation of America articulated a broad vision that includes advocating for improved care and quality of life for those affected by bleeding disorders. Hemophilia imposes many burdens: painful and unpredictable bleeding; joint damage or other serious long-term complications; onerous treatment regimens; and numerous other constraints on personal and family life. HFA […]
English 
Español de Puerto Rico